Update June 2022: Terminated (A business decision was made to discontinue further enrolment. There were no safety concerns that contributed to this decision.)

FIGHT-207 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib in participants with activating FGFR mutations or translocations.

Full title: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

For more details of the study, go to:

Also, see: and search for Study: FIGHT-207


Back to previous page